UK among top performers in access to healthcare, says new report
The Global Access to Healthcare Index measures how healthcare systems across 60 countries are working to solve the most pressing healthcare needs...
List view / Grid view
The Global Access to Healthcare Index measures how healthcare systems across 60 countries are working to solve the most pressing healthcare needs...
Dolomite Microfluidics is making microencapsulation technology more widely accessible with the Telos® droplet system, designed for high throughput and easy scale up...
A new deal on the breast cancer drug trastuzumab emtansine means that it can now be recommended for routine funding.
The FDA has accepted Sandoz’s New Drug Application for fluticasone propionate / salmeterol combination product, a generic version of Advair Diskus...
More work needs to be done to examine the real world effects of the commonly prescribed diabetes drug empagliflozin, new research finds...
The European Medicines Agency (EMA) and the European Commission have published guidance to help pharmaceutical companies prepare for the United Kingdom's withdrawal from the European Union.
The European Medicines Agency (EMA) has published an action plan that aims to foster innovation and support small and medium-sized enterprises (SMEs) in the development of novel human and veterinary medicines.
The Association for Accessible Medicines (AAM) applauded the US Supreme Court’s decision this week in Sandoz Inc. v. Amgen Inc. that will help speed patient access to biosimilar versions of expensive brand-name biologic medicines.
In 2018, industry leaders from pharma, biotech and clinical research organisations will advance the participation of patients in clinical trials...
SmartAction and EndPoint Technologies have formed a strategic partnership to expand the availability of AI-powered customer technology.
Lab Innovations – the UK’s only dedicated showcase for laboratory technology, analytical and biotech equipment – returns for its sixth consecutive year on 1 & 2 November 2017 at the NEC, Birmingham...
A key session opens up the challenges of delivering personalized genetic medicines...
Valeant Pharmaceuticals has entered into an agreement to sell its iNova Pharmaceuticals business for $930 million in cash.
A new report released by the UK BioIndustry Association (BIA) shows that the UK maintained its strong leadership position in European biotech funding last year and has the strongest pipeline in Europe for future drug development.
Collaboration between the pharmaceutical industry, patients and health regulators will be a ‘game changer’ in delivering exciting new cell and gene therapies to treat conditions like cancer and vision loss.